Skip to main content
. 2022 Feb 20;77:103888. doi: 10.1016/j.ebiom.2022.103888

Table 3.

IgM-S and IgG-S development following the two doses vaccination with BNT162b2, Vaxveria and Spikevax vaccines.

IgM-SNEG IgM-SPOS Total
BNT162b2 -Pfizer/BionTech 573 (36.2%) 1011 (63.8%) 1584
Vaxzevria-AstraZeneca 31 (83.8%) 6 (16.2%) 37
Spikevax-Moderna 13 (86.7%) 2 (13.3%) 15